Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,22155501,area under the curve (AUC),"The daily target area under the curve (AUC) was 18,125-20,000 μg*h/L/day (4415-4872 μmol*min/L/day), which was reduced to 18,000-19,000 μg*h/L/day (4384-4628 μmol*min/L/day) after a high incidence of toxicity was observed.",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[h·μg] / [d·l],"18,125-20,000",8623,DB01073,Fludarabine
,22155501,area under the curve (AUC),"The daily target area under the curve (AUC) was 18,125-20,000 μg*h/L/day (4415-4872 μmol*min/L/day), which was reduced to 18,000-19,000 μg*h/L/day (4384-4628 μmol*min/L/day) after a high incidence of toxicity was observed.",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[min·μM] / [d·l],4415-4872,8624,DB01073,Fludarabine
,22155501,area under the curve (AUC),"The daily target area under the curve (AUC) was 18,125-20,000 μg*h/L/day (4415-4872 μmol*min/L/day), which was reduced to 18,000-19,000 μg*h/L/day (4384-4628 μmol*min/L/day) after a high incidence of toxicity was observed.",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[h·μg] / [d·l],"18,000-19,000",8625,DB01073,Fludarabine
,22155501,area under the curve (AUC),"The daily target area under the curve (AUC) was 18,125-20,000 μg*h/L/day (4415-4872 μmol*min/L/day), which was reduced to 18,000-19,000 μg*h/L/day (4384-4628 μmol*min/L/day) after a high incidence of toxicity was observed.",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[min·μM] / [d·l],4384-4628,8626,DB01073,Fludarabine
,22155501,AUC,"After infusion of busulfan on the first day, patients showed AUC that ranged from 12,079 to 31,660 μg*h/L (2942 to 7712 μmol*min/L) (median 16,824 μg*h/L, percent coefficient of variation (%CV) = 26.5%), with clearance of 1.74-6.94 mL/min/kg (median 4.03 mL/min/kg).",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[h·μg] / [l],"12,079 to 31,660",8627,DB01073,Fludarabine
,22155501,AUC,"After infusion of busulfan on the first day, patients showed AUC that ranged from 12,079 to 31,660 μg*h/L (2942 to 7712 μmol*min/L) (median 16,824 μg*h/L, percent coefficient of variation (%CV) = 26.5%), with clearance of 1.74-6.94 mL/min/kg (median 4.03 mL/min/kg).",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[min·μM] / [l],2942 to 7712,8628,DB01073,Fludarabine
,22155501,AUC,"After infusion of busulfan on the first day, patients showed AUC that ranged from 12,079 to 31,660 μg*h/L (2942 to 7712 μmol*min/L) (median 16,824 μg*h/L, percent coefficient of variation (%CV) = 26.5%), with clearance of 1.74-6.94 mL/min/kg (median 4.03 mL/min/kg).",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[h·μg] / [l],"16,824",8629,DB01073,Fludarabine
,22155501,clearance,"After infusion of busulfan on the first day, patients showed AUC that ranged from 12,079 to 31,660 μg*h/L (2942 to 7712 μmol*min/L) (median 16,824 μg*h/L, percent coefficient of variation (%CV) = 26.5%), with clearance of 1.74-6.94 mL/min/kg (median 4.03 mL/min/kg).",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[ml] / [kg·min],1.74-6.94,8630,DB01073,Fludarabine
,22155501,clearance,"After infusion of busulfan on the first day, patients showed AUC that ranged from 12,079 to 31,660 μg*h/L (2942 to 7712 μmol*min/L) (median 16,824 μg*h/L, percent coefficient of variation (%CV) = 26.5%), with clearance of 1.74-6.94 mL/min/kg (median 4.03 mL/min/kg).",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[ml] / [kg·min],4.03,8631,DB01073,Fludarabine
less,22155501,total AUC,"Graft failure occurred in 3 patients with total AUC less than 74,000 μg*h/L (18,026 μmol*min/L), and 2 patients with relatively high total AUC experienced veno-occlusive disease.",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[h·μg] / [l],"74,000",8632,DB01073,Fludarabine
,22155501,total AUC,"Graft failure occurred in 3 patients with total AUC less than 74,000 μg*h/L (18,026 μmol*min/L), and 2 patients with relatively high total AUC experienced veno-occlusive disease.",Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155501/),[min·μM] / [l],"18,026",8633,DB01073,Fludarabine
,30051172,area-under-the-concentration-versus-time curve (AUC),"Thirty-seven patients received PK-adjusted dosing guided by the results of the initial PK results, targeting a specific Bu exposure expressed as the area-under-the-concentration-versus-time curve (AUC) of between 4000 and 5000 μmol min/day (median 4800).",The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30051172/),[min·μM] / [d],4000 and 5000,9962,DB01073,Fludarabine
,30051172,area-under-the-concentration-versus-time curve (AUC),"Thirty-seven patients received PK-adjusted dosing guided by the results of the initial PK results, targeting a specific Bu exposure expressed as the area-under-the-concentration-versus-time curve (AUC) of between 4000 and 5000 μmol min/day (median 4800).",The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30051172/),[min·μM] / [d],4800,9963,DB01073,Fludarabine
,30051172,AUC,"For the purposes of the analysis, we selected a target AUC of 4800 μmol min/day in this group, equivalent to the median targeted AUC in the PK-adjusted group.",The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30051172/),[min·μM] / [d],4800,9964,DB01073,Fludarabine
,30051172,AUCs,The respective median AUCs of 5064 μmol min/day (range 3639-6157 μmol min/day) and 4854 μmol min/day (range 3251-6305 μmol min/day) were not significantly different (p = 0.16).,The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30051172/),[min·μM] / [d],5064,9965,DB01073,Fludarabine
,30051172,AUCs,The respective median AUCs of 5064 μmol min/day (range 3639-6157 μmol min/day) and 4854 μmol min/day (range 3251-6305 μmol min/day) were not significantly different (p = 0.16).,The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30051172/),[min·μM] / [d],4854,9966,DB01073,Fludarabine
>,30051172,AUCs,"No correlation between AUC and grade 3-4 transplant-related toxicities were observed, although only three patients had AUCs > 6000 μmol min/day.",The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30051172/),[min·μM] / [d],6000,9967,DB01073,Fludarabine
,28807770,areas under the curve (AUCs),"The measured areas under the curve (AUCs) were within target (900 to 1500 µM/min) in 38.7% of patients after the administration of the first dose calculated based on age and weight, as locally recommended.",GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28807770/),[μM] / [min],900 to 1500,12741,DB01073,Fludarabine
,17211431,AUC,"AUC, C(max), t(1/2), Cl(total) and V(SS) were 21.9 microMh, 3.5 microM, 13.0 h, 4.3 l/h/m(2), 60.0 l/m(2) on day -6 and 22.4 microMh, 3.5 microM, 14.0 h, 4.7 l/h/m(2), 69.0 l/m(2) on day -5 to (-2), respectively.",F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211431/),μMh,21.9,12761,DB01073,Fludarabine
,17211431,t(1/2),"AUC, C(max), t(1/2), Cl(total) and V(SS) were 21.9 microMh, 3.5 microM, 13.0 h, 4.3 l/h/m(2), 60.0 l/m(2) on day -6 and 22.4 microMh, 3.5 microM, 14.0 h, 4.7 l/h/m(2), 69.0 l/m(2) on day -5 to (-2), respectively.",F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211431/),μM,3.5,12762,DB01073,Fludarabine
,17211431,t(1/2),"AUC, C(max), t(1/2), Cl(total) and V(SS) were 21.9 microMh, 3.5 microM, 13.0 h, 4.3 l/h/m(2), 60.0 l/m(2) on day -6 and 22.4 microMh, 3.5 microM, 14.0 h, 4.7 l/h/m(2), 69.0 l/m(2) on day -5 to (-2), respectively.",F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211431/),[h·l] / [m(2],4.7,12763,DB01073,Fludarabine
,17211431,Cl(total),"AUC, C(max), t(1/2), Cl(total) and V(SS) were 21.9 microMh, 3.5 microM, 13.0 h, 4.3 l/h/m(2), 60.0 l/m(2) on day -6 and 22.4 microMh, 3.5 microM, 14.0 h, 4.7 l/h/m(2), 69.0 l/m(2) on day -5 to (-2), respectively.",F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211431/),μM,3.5,12764,DB01073,Fludarabine
,17211431,Cl(total),"AUC, C(max), t(1/2), Cl(total) and V(SS) were 21.9 microMh, 3.5 microM, 13.0 h, 4.3 l/h/m(2), 60.0 l/m(2) on day -6 and 22.4 microMh, 3.5 microM, 14.0 h, 4.7 l/h/m(2), 69.0 l/m(2) on day -5 to (-2), respectively.",F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211431/),[h·l] / [m(2],4.7,12765,DB01073,Fludarabine
,17211431,V(SS),"AUC, C(max), t(1/2), Cl(total) and V(SS) were 21.9 microMh, 3.5 microM, 13.0 h, 4.3 l/h/m(2), 60.0 l/m(2) on day -6 and 22.4 microMh, 3.5 microM, 14.0 h, 4.7 l/h/m(2), 69.0 l/m(2) on day -5 to (-2), respectively.",F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211431/),[l] / [m(2],69.0,12766,DB01073,Fludarabine
,17211431,Cl(renal),"Cl(renal) and the urine-recovery were 4.8 l/h, 43.7% of the fludarabine dose on day -6 and 3.9 l/h, 44.2% of the fludarabine dose on day -5 to (-2), respectively.",F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211431/),[l] / [h],4.8,12767,DB01073,Fludarabine
,17211431,Cl(renal),"Cl(renal) and the urine-recovery were 4.8 l/h, 43.7% of the fludarabine dose on day -6 and 3.9 l/h, 44.2% of the fludarabine dose on day -5 to (-2), respectively.",F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211431/),[l] / [h],3.9,12768,DB01073,Fludarabine
<,27094990,clearance (Clpred),"In the independent cohort, the hazard ratio of NRM at day 100 was significantly higher in patients with predicted F-ara-A clearance (Clpred) <8.50 L/h (P < 0.01) and area under the curve (AUCpred) >6.00 μg × h/mL (P = 0.01).",Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27094990/),[l] / [h],8.50,15216,DB01073,Fludarabine
>,27094990,area under the curve (AUCpred),"In the independent cohort, the hazard ratio of NRM at day 100 was significantly higher in patients with predicted F-ara-A clearance (Clpred) <8.50 L/h (P < 0.01) and area under the curve (AUCpred) >6.00 μg × h/mL (P = 0.01).",Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27094990/),[h·μg] / [ml],6.00,15217,DB01073,Fludarabine
,30512187,AUC1,"The mean AUC1 was 7.20 ± 1.48 mg • h/L, which ranged from 4.70 to 9.46 mg • h/L.",Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30512187/),[h·mg] / [l],7.20,20380,DB01073,Fludarabine
below,30512187,AUC1,The AUC1 was below the therapeutic concentration of 7.38 mg • h/L in 45% (9 of 20) of the patients.,Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30512187/),[h·mg] / [l],7.38,20381,DB01073,Fludarabine
,30512187,CLT,The CLT of 3.05 ± 0.56 mL/min/kg was not significantly different with the CL1 of 3.03 ± 0.69 mL/min/kg (P = .901).,Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30512187/),[ml] / [kg·min],3.05,20382,DB01073,Fludarabine
,30512187,CL1,The CLT of 3.05 ± 0.56 mL/min/kg was not significantly different with the CL1 of 3.03 ± 0.69 mL/min/kg (P = .901).,Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30512187/),[ml] / [kg·min],3.03,20383,DB01073,Fludarabine
,25659459,time from diagnosis to HCT,"The median number of previous therapies was 3 (range, 1-8) and median time from diagnosis to HCT was 32 months (range, 4.5-177.5 months).",Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25659459/),month,32,21467,DB01073,Fludarabine
,25659459,overall survival,"Three-year progression-free and overall survival for all patients was 47.8% and 55%, respectively.",Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25659459/),,55,21468,DB01073,Fludarabine
,2477118,"t1/2,el","F-araATP accumulated to approximately 1 mM in P388 cells after either LD1 or LD50 treatment of F-araAMP and was eliminated with a t1/2,el of approximately 5 h.",Pharmacodynamics and proposed mechanism of therapeutic action and host toxicity of 9-beta-D-arabinofuranosyl-2-fluoroadenine monophosphate (F-araAMP) in P388 murine leukemia-bearing mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2477118/),h,5,21931,DB01073,Fludarabine
,2477118,ratio of % lethality (LD50/LD1,"The ratio of area under the curve (AUC) of F-ATP in P388 cells after the two doses of F-araAMP was 38.77, which approaches the ratio of % lethality (LD50/LD1 = 50).",Pharmacodynamics and proposed mechanism of therapeutic action and host toxicity of 9-beta-D-arabinofuranosyl-2-fluoroadenine monophosphate (F-araAMP) in P388 murine leukemia-bearing mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2477118/),,50,21932,DB01073,Fludarabine
exceeds,21801704,area under the plasma concentration versus time curve (AUC),"Therapeutic drug monitoring is recommended as nonrelapse mortality increases when daily exposure, as determined by the area under the plasma concentration versus time curve (AUC), exceeds 6000 μM·min.",Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21801704/),min·μM,6000,22433,DB01073,Fludarabine
>,21801704,AUC,"In 24 individuals, the test dose predicted an AUC >5500 μM·min; therefore, the first Bu treatment dose was reduced to a desired target AUC.",Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21801704/),min·μM,5500,22434,DB01073,Fludarabine
,9516951,maximum tolerated plasma concentrations,"The maximum tolerated plasma concentrations for this combination regimen was 10 microM fludarabine for 48 h followed by 72 h of 15 microM ara-C, which were achieved at dose level 3.",Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9516951/),μM,10,23245,DB01073,Fludarabine
,20225334,response rate,A previous study of intravenous (iv) bolus alemtuzumab plus rituximab in patients with chronic lymphocytic leukemia (CLL) recurrence produced a response rate of 54% after a 4-week treatment period.,Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20225334/),%,54,25943,DB01073,Fludarabine
,20225334,overall response rate,"Seven patients (18%) achieved a complete response (CR), 4 (10%) a nodular partial response (nPR), and 10 (25%) a partial response for an overall response rate of 53%.",Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20225334/),%,53,25944,DB01073,Fludarabine
,32886279,area under the blood concentration-time curve,"In BuFlu, the median area under the blood concentration-time curve of Bu on the fourth day was 1183 μmol min/L (range 808-1509), which was significantly higher than that on the first day [1095 μmol min/L (range 822-1453), P < 0.01].",Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886279/),[min·μM] / [l],1183,29910,DB01073,Fludarabine
,32886279,area under the blood concentration-time curve,"In BuFlu, the median area under the blood concentration-time curve of Bu on the fourth day was 1183 μmol min/L (range 808-1509), which was significantly higher than that on the first day [1095 μmol min/L (range 822-1453), P < 0.01].",Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886279/),[min·μM] / [l],1095,29911,DB01073,Fludarabine
,12374451,Relapse rates,"Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and 18% for 17 patients with other active malignancy.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,21,30243,DB01073,Fludarabine
,12374451,Relapse rates,"Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and 18% for 17 patients with other active malignancy.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,66,30244,DB01073,Fludarabine
,12374451,Relapse rates,"Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and 18% for 17 patients with other active malignancy.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,18,30245,DB01073,Fludarabine
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,74,30246,DB01073,Fludarabine
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,26,30247,DB01073,Fludarabine
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,37,30248,DB01073,Fludarabine
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,65,30249,DB01073,Fludarabine
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,88,30250,DB01073,Fludarabine
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,26,30251,DB01073,Fludarabine
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,37,30252,DB01073,Fludarabine
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,65,30253,DB01073,Fludarabine
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,71,30254,DB01073,Fludarabine
,12374451,half-lives,"Kinetics were linear, and for the first and fourth doses, the half-lives were 2.60 +/- 0.44 and 2.57 +/- 0.36 hours, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),h,2.60,30255,DB01073,Fludarabine
,12374451,half-lives,"Kinetics were linear, and for the first and fourth doses, the half-lives were 2.60 +/- 0.44 and 2.57 +/- 0.36 hours, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),h,2.57,30256,DB01073,Fludarabine
,12374451,Clearances,"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[ml] / [m2·min],106.77,30257,DB01073,Fludarabine
,12374451,Clearances,"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[ml] / [m2·min],106.86,30258,DB01073,Fludarabine
,12374451,peak concentrations (Cmax),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[mcg] / [ml],3.92,30259,DB01073,Fludarabine
,12374451,peak concentrations (Cmax),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[mcg] / [ml],3.96,30260,DB01073,Fludarabine
,12374451,areas under the plasma concentration versus time curve (AUC),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),min·μM,4866.51,30261,DB01073,Fludarabine
,12374451,areas under the plasma concentration versus time curve (AUC),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),min·μM,4980,30262,DB01073,Fludarabine
,27130252,Css,"In 81% of the patients who received BU doses adjusted based on the test dose (n = 21), the Css was within the target range of 600-900 ng/mL.",Use of an Oral Busulfan Test Dose in Patients Undergoing Hematopoietic Stem Cell Transplantation Treated With or Without Fludarabine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27130252/),[ng] / [ml],600-900,30574,DB01073,Fludarabine
,22198540,AUC levels,"Three target AUC levels were planned: 6,000, 7,500, and 9,000 μM-min.",Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22198540/),μM-min,"6,000",38404,DB01073,Fludarabine
,22198540,AUC levels,"Three target AUC levels were planned: 6,000, 7,500, and 9,000 μM-min.",Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22198540/),μM-min,"7,500",38405,DB01073,Fludarabine
,22198540,AUC levels,"Three target AUC levels were planned: 6,000, 7,500, and 9,000 μM-min.",Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22198540/),μM-min,"9,000",38406,DB01073,Fludarabine
,22198540,AUC,"For level 1 patients, i.v. busulfan doses 1 and 2 were 170 mg/m(2)/day, then doses 3 and 4 were adjusted based on first-dose pharmacokinetic modeling to achieve an average daily AUC of 6,000 μM-min.",Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22198540/),μM-min,"6,000",38407,DB01073,Fludarabine
,22198540,AUC,"Doses 1 and 2 for the subsequent cohorts were based on the level 1 data: 180 mg/m(2)/day for AUC 7,500 μM-min (level 2) and 220 mg/m(2)/day for AUC 9,000 μM-min (level 3), with pharmacokinetic targeting for doses 3 and 4.",Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22198540/),μM-min,"7,500",38408,DB01073,Fludarabine
,22198540,AUC,"Doses 1 and 2 for the subsequent cohorts were based on the level 1 data: 180 mg/m(2)/day for AUC 7,500 μM-min (level 2) and 220 mg/m(2)/day for AUC 9,000 μM-min (level 3), with pharmacokinetic targeting for doses 3 and 4.",Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22198540/),μM-min,"9,000",38409,DB01073,Fludarabine
,22198540,AUC,"Within the confines of the trial's small sample size, there was no suggestion that escalating busulfan AUC from 6,000 to 7,500 μM-min × 4 days increased nonrelapse mortality.",Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22198540/),4·d·μM-min,6,38410,DB01073,Fludarabine
,16578989,area under the plasma concentration-time curve (AUC),"The mean area under the plasma concentration-time curve (AUC) and the half-life of the first dose of intravenously administered busulfan were 6,253 microM x minute (range, 5,036-7,482 microM x minute) and 3.37 hours (range, 2.54-4.00 hours), respectively.",Phase I and pharmacokinetic study of once-daily dosing of intravenously administered busulfan in the setting of a reduced-intensity preparative regimen and allogeneic hematopoietic stem cell transplantation as immunotherapy for renal cell carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16578989/),min·μM,"6,253",38991,DB01073,Fludarabine
,16578989,half-life,"The mean area under the plasma concentration-time curve (AUC) and the half-life of the first dose of intravenously administered busulfan were 6,253 microM x minute (range, 5,036-7,482 microM x minute) and 3.37 hours (range, 2.54-4.00 hours), respectively.",Phase I and pharmacokinetic study of once-daily dosing of intravenously administered busulfan in the setting of a reduced-intensity preparative regimen and allogeneic hematopoietic stem cell transplantation as immunotherapy for renal cell carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16578989/),h,3.37,38992,DB01073,Fludarabine
,32493164,Overall survival,"Overall survival was shorter in patients with a lower Hb (113 vs. 2536 days; p = 0.004), due to an increased rate of nonrelapse mortality (NRM) (p = 0.0005).","Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32493164/),d,113,41430,DB01073,Fludarabine
,32493164,Overall survival,"Overall survival was shorter in patients with a lower Hb (113 vs. 2536 days; p = 0.004), due to an increased rate of nonrelapse mortality (NRM) (p = 0.0005).","Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32493164/),d,2536,41431,DB01073,Fludarabine
,32493164,Overall survival,"Overall survival was also worse in patients with lower CrCl (75 vs. 317 days; p = 0.003), with a significantly worse nonrelapse mortality (p = 0.0023).","Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32493164/),d,75,41432,DB01073,Fludarabine
,32493164,Overall survival,"Overall survival was also worse in patients with lower CrCl (75 vs. 317 days; p = 0.003), with a significantly worse nonrelapse mortality (p = 0.0023).","Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32493164/),d,317,41433,DB01073,Fludarabine
,20347037,clearance,"Clofarabine clearance was significantly reduced upon co-administration with, cimetidine (0.83+/-0.22-->0.32+/-0.058mL/min).",Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20347037/),[ml] / [min],0.83,43396,DB01073,Fludarabine
,20347037,clearance,"Clofarabine clearance was significantly reduced upon co-administration with, cimetidine (0.83+/-0.22-->0.32+/-0.058mL/min).",Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20347037/),[ml] / [min],0.32,43397,DB01073,Fludarabine
,20347037,clearance,"In vivo data correlated with IPK results as clofarabine clearance decreased 61% (20.2-7.80mL/min/kg), upon co-administration with cimetidine in rats.",Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20347037/),[ml] / [kg·min],20.2-7.80,43398,DB01073,Fludarabine
,23777614,extraction recoveries,"The extraction recoveries were 85% for fludarabine and 95% for the internal standard, which represent a significant improvement over the previously published methods.",Improved quantitative method for fludarabine in human plasma by liquid chromatography and tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777614/),%,85,46188,DB01073,Fludarabine
,23777614,extraction recoveries,"The extraction recoveries were 85% for fludarabine and 95% for the internal standard, which represent a significant improvement over the previously published methods.",Improved quantitative method for fludarabine in human plasma by liquid chromatography and tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777614/),%,95,46189,DB01073,Fludarabine
,2431803,terminal half-lives of elimination,The terminal half-lives of elimination of both F-ara-A (8 h) in plasma and intracellular F-ara-ATP (15 h) were not dependent upon the dose of F-ara-AMP.,9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2431803/),h,8,47442,DB01073,Fludarabine
,2431803,terminal half-lives of elimination,The terminal half-lives of elimination of both F-ara-A (8 h) in plasma and intracellular F-ara-ATP (15 h) were not dependent upon the dose of F-ara-AMP.,9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2431803/),h,15,47443,DB01073,Fludarabine
,31002993,clearance (CL),"Final parameter estimates for clo-fara were consistent with previous reports and were as follows: clearance (CL), 23 L/h/15 kg; volume of the central compartment, 42 L/15 kg; volume of peripheral compartment, 47 L/15 kg; and intercompartmental CL, 9.8 L/h/15 kg.",Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31002993/),[l] / [15·h·kg],23,48454,DB01073,Fludarabine
,31002993,volume of the central compartment,"Final parameter estimates for clo-fara were consistent with previous reports and were as follows: clearance (CL), 23 L/h/15 kg; volume of the central compartment, 42 L/15 kg; volume of peripheral compartment, 47 L/15 kg; and intercompartmental CL, 9.8 L/h/15 kg.",Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31002993/),[l] / [15·kg],42,48455,DB01073,Fludarabine
,31002993,volume of peripheral compartment,"Final parameter estimates for clo-fara were consistent with previous reports and were as follows: clearance (CL), 23 L/h/15 kg; volume of the central compartment, 42 L/15 kg; volume of peripheral compartment, 47 L/15 kg; and intercompartmental CL, 9.8 L/h/15 kg.",Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31002993/),[l] / [15·kg],47,48456,DB01073,Fludarabine
,31002993,intercompartmental CL,"Final parameter estimates for clo-fara were consistent with previous reports and were as follows: clearance (CL), 23 L/h/15 kg; volume of the central compartment, 42 L/15 kg; volume of peripheral compartment, 47 L/15 kg; and intercompartmental CL, 9.8 L/h/15 kg.",Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31002993/),[l] / [15·h·kg],9.8,48457,DB01073,Fludarabine
,31002993,AUC0-24,"For example, the dose required for a 6-month and 1-year old was approximately 43% and 17% lower, respectively, than the typical 40 mg/m2dose to achieve the median AUC0-24of 1.04 mg·h/L in the study population.",Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31002993/),[h·mg] / [l],1.04,48458,DB01073,Fludarabine
,20919852,AUC,Busulfan levels after a test dose and conditioning dose 1 allowed targeting of subsequent AUCs and dose-escalation above the starting AUC of 4800 µmol-min/L.,Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919852/),[µmol-min] / [l],4800,51678,DB01073,Fludarabine
,20919852,AUC,"Severe, late-occurring sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) was the dose-limiting toxicity seen in 5/8 patients at an AUC level of 6800 µmol-min/L.",Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919852/),[µmol-min] / [l],6800,51679,DB01073,Fludarabine
,20919852,maximum-tolerated AUC,Busulfan dose-escalation to a maximum-tolerated AUC of 5800 µmol-min/L-higher than that achieved by current standard busulfan regimens-was accurate and achievable using real-time pharmacokinetics monitoring of the first conditioning dose.,Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919852/),[µmol-min] / [l],5800,51680,DB01073,Fludarabine
,2427240,distribution half-life (t1/2 alpha),Computer fitting of the plasma concentration-time curves yielded an average distribution half-life (t1/2 alpha) of 0.60 h and a terminal half-life (t1/2 beta) of 9.3 h.,Pharmacokinetic study of fludarabine phosphate (NSC 312887). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427240/),h,0.60,54037,DB01073,Fludarabine
,2427240,terminal half-life (t1/2 beta),Computer fitting of the plasma concentration-time curves yielded an average distribution half-life (t1/2 alpha) of 0.60 h and a terminal half-life (t1/2 beta) of 9.3 h.,Pharmacokinetic study of fludarabine phosphate (NSC 312887). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427240/),h,9.3,54038,DB01073,Fludarabine
,2427240,plasma clearance,"The estimated plasma clearance was 9.07 +/- 3.77 l/h per m2 and the steady state volume of distribution, 96.2 +/- 26.0 l/m2.",Pharmacokinetic study of fludarabine phosphate (NSC 312887). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427240/),[l] / [h·m2],9.07,54039,DB01073,Fludarabine
,2427240,steady state volume of distribution,"The estimated plasma clearance was 9.07 +/- 3.77 l/h per m2 and the steady state volume of distribution, 96.2 +/- 26.0 l/m2.",Pharmacokinetic study of fludarabine phosphate (NSC 312887). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427240/),[l] / [m2],96.2,54040,DB01073,Fludarabine
,28089878,maximum alemtuzumab concentration,"The median maximum alemtuzumab concentration was 2.39 µg/mL (interquartile range, 1.98 to 2.92).",Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28089878/),[μg] / [ml],2.39,54118,DB01073,Fludarabine
,28089878,terminal half-life,"The median terminal half-life was 5.2 days (interquartile range, 2.7 to 7.8).",Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28089878/),d,5.2,54119,DB01073,Fludarabine
,23955479,apparent clearance,Patients concomitantly treated with fludarabine showed reduced apparent clearance of busulfan (110.5 mL/h/kg vs. 157.4 mL/h/kg) and higher AUC0-6 (area under the plasma concentrations vs. time curve) than patients subsequently treated with cyclophosphamide (7.9 µg h/mL vs. 5.7 µg h/mL).,Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23955479/),[ml] / [h·kg],110.5,69628,DB01073,Fludarabine
,23955479,apparent clearance,Patients concomitantly treated with fludarabine showed reduced apparent clearance of busulfan (110.5 mL/h/kg vs. 157.4 mL/h/kg) and higher AUC0-6 (area under the plasma concentrations vs. time curve) than patients subsequently treated with cyclophosphamide (7.9 µg h/mL vs. 5.7 µg h/mL).,Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23955479/),[ml] / [h·kg],157.4,69629,DB01073,Fludarabine
,23955479,AUC0-6 (area under the plasma concentrations vs. time curve,Patients concomitantly treated with fludarabine showed reduced apparent clearance of busulfan (110.5 mL/h/kg vs. 157.4 mL/h/kg) and higher AUC0-6 (area under the plasma concentrations vs. time curve) than patients subsequently treated with cyclophosphamide (7.9 µg h/mL vs. 5.7 µg h/mL).,Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23955479/),[h·μg] / [ml],7.9,69630,DB01073,Fludarabine
,23955479,AUC0-6 (area under the plasma concentrations vs. time curve,Patients concomitantly treated with fludarabine showed reduced apparent clearance of busulfan (110.5 mL/h/kg vs. 157.4 mL/h/kg) and higher AUC0-6 (area under the plasma concentrations vs. time curve) than patients subsequently treated with cyclophosphamide (7.9 µg h/mL vs. 5.7 µg h/mL).,Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23955479/),[h·μg] / [ml],5.7,69631,DB01073,Fludarabine
,18489992,Relapse rate,Relapse rate was 25% at 2 years.,Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18489992/),%,25,71153,DB01073,Fludarabine
,21132026,area under the concentration-time curve (AUC),BU was given once daily at 130 mg/m(2) per day on days 1 and 2; doses for days 3 and 4 were adjusted in 92 patients (63%) to an average daily area under the concentration-time curve (AUC) of 5300 μM/min.,Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21132026/),[μM] / [min],5300,71274,DB01073,Fludarabine
,21132026,clearance,Women had higher clearance than men (median 2.9 vs 2.5 mL/min/kg; P=0.001).,Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21132026/),[ml] / [kg·min],2.9,71275,DB01073,Fludarabine
,21132026,clearance,Women had higher clearance than men (median 2.9 vs 2.5 mL/min/kg; P=0.001).,Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21132026/),[ml] / [kg·min],2.5,71276,DB01073,Fludarabine
,34329753,area under the curve,"The dosing of busulfan was determined from pharmacokinetic analyses to achieve for the course a target area under the curve of 20,000 ± 12% μmol/min, which is close to the average exposure of myeloablative dose of busulfan.",Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34329753/),[%·μM] / [min],"20,000",73468,DB01073,Fludarabine
,1699279,t1/2 alpha,"The 2-F-ara-A harmonic mean half-lives were t1/2 alpha = 4.97 minutes, t1/2 beta = 1.38 hours, t1/2 gamma = 10.41 hours, and the mean residence time was 10.51 hours.",Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),min,4.97,77345,DB01073,Fludarabine
,1699279,t1/2 beta,"The 2-F-ara-A harmonic mean half-lives were t1/2 alpha = 4.97 minutes, t1/2 beta = 1.38 hours, t1/2 gamma = 10.41 hours, and the mean residence time was 10.51 hours.",Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),h,1.38,77346,DB01073,Fludarabine
,1699279,t1/2 gamma,"The 2-F-ara-A harmonic mean half-lives were t1/2 alpha = 4.97 minutes, t1/2 beta = 1.38 hours, t1/2 gamma = 10.41 hours, and the mean residence time was 10.51 hours.",Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),h,10.41,77347,DB01073,Fludarabine
,1699279,mean residence time,"The 2-F-ara-A harmonic mean half-lives were t1/2 alpha = 4.97 minutes, t1/2 beta = 1.38 hours, t1/2 gamma = 10.41 hours, and the mean residence time was 10.51 hours.",Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),h,10.51,77348,DB01073,Fludarabine
,1699279,total-body plasma clearance,The mean total-body plasma clearance was 67.98 +/- 19.58 mL/min/m2 (mean +/- SD).,Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),[ml] / [m2·min],67.98,77349,DB01073,Fludarabine
,1699279,central compartment volume of distribution (V1),The mean central compartment volume of distribution (V1) was 7.49 L/m2 or 0.20 L/kg.,Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),[l] / [m2],7.49,77350,DB01073,Fludarabine
,1699279,central compartment volume of distribution (V1),The mean central compartment volume of distribution (V1) was 7.49 L/m2 or 0.20 L/kg.,Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),[l] / [kg],0.20,77351,DB01073,Fludarabine
,1699279,steady-state volume of distribution (Vdss),"The mean steady-state volume of distribution (Vdss) was 44.17 L/m2 or 1.19 L/kg, indicating that 2-F-ara-A is distributed and bound to the tissues of the body.",Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),[l] / [m2],44.17,77352,DB01073,Fludarabine
,1699279,steady-state volume of distribution (Vdss),"The mean steady-state volume of distribution (Vdss) was 44.17 L/m2 or 1.19 L/kg, indicating that 2-F-ara-A is distributed and bound to the tissues of the body.",Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),[l] / [kg],1.19,77353,DB01073,Fludarabine
,16144801,concentration steady state (Css),"Comparing the twice-daily and 3-times-daily MMF groups, the mean total MPA concentration steady state (Css) was 1.9 and 3.1 microg/mL; the unbound Css was 18 and 36 ng/mL, respectively (P < .001).",Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[μg] / [ml],1.9,84891,DB01073,Fludarabine
,16144801,concentration steady state (Css),"Comparing the twice-daily and 3-times-daily MMF groups, the mean total MPA concentration steady state (Css) was 1.9 and 3.1 microg/mL; the unbound Css was 18 and 36 ng/mL, respectively (P < .001).",Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[μg] / [ml],3.1,84892,DB01073,Fludarabine
,16144801,unbound Css,"Comparing the twice-daily and 3-times-daily MMF groups, the mean total MPA concentration steady state (Css) was 1.9 and 3.1 microg/mL; the unbound Css was 18 and 36 ng/mL, respectively (P < .001).",Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[ng] / [ml],18,84893,DB01073,Fludarabine
,16144801,unbound Css,"Comparing the twice-daily and 3-times-daily MMF groups, the mean total MPA concentration steady state (Css) was 1.9 and 3.1 microg/mL; the unbound Css was 18 and 36 ng/mL, respectively (P < .001).",Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[ng] / [ml],36,84894,DB01073,Fludarabine
less,16144801,Css,"Sixteen patients with a total MPA Css less than 3 microg/mL had low (< 50%) donor T-cell chimerism (P = .03), and 6 patients with MPA Css less than 2.5 microg/mL had graft rejection.",Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[μg] / [ml],3,84895,DB01073,Fludarabine
less,16144801,Css,"Sixteen patients with a total MPA Css less than 3 microg/mL had low (< 50%) donor T-cell chimerism (P = .03), and 6 patients with MPA Css less than 2.5 microg/mL had graft rejection.",Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[μg] / [ml],2.5,84896,DB01073,Fludarabine
greater,16144801,Css's,We conclude that increased MPA Css's predicted higher degrees of donor T-cell chimerism after unrelated donor nonmyeloablative HCT and suggest that targeting MPA Css's greater than 2.5 microg/mL could prevent graft rejection.,Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[μg] / [ml],2.5,84897,DB01073,Fludarabine
,15571270,maximum tolerated dose (MTD),Phase I studies among 32 patients with acute leukemia defined a maximum tolerated dose (MTD) of 40 mg/m2/d given as a one hour infusion daily for 5 days.,Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15571270/),[mg] / [d·m2],40,95777,DB01073,Fludarabine
,15571270,overall response rate,"Twenty patients (32%) achieved complete response (CR), 1 had a partial response (PR), and 9 had a CR but without platelet recovery (CRp), for an overall response rate of 48%.",Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15571270/),%,48,95778,DB01073,Fludarabine
,14524733,overall response rate,"Depending on the criteria used, the overall response rate was 46.2% (20.5% complete response [CR], 25.6% partial response [PR]) or 51.3% (17.9% CR, 33.3% PR).",Oral fludarabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14524733/),%,46.2,96298,DB01073,Fludarabine
,14524733,overall response rate,"Depending on the criteria used, the overall response rate was 46.2% (20.5% complete response [CR], 25.6% partial response [PR]) or 51.3% (17.9% CR, 33.3% PR).",Oral fludarabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14524733/),%,20.5,96299,DB01073,Fludarabine
,14524733,overall response rate,"Depending on the criteria used, the overall response rate was 46.2% (20.5% complete response [CR], 25.6% partial response [PR]) or 51.3% (17.9% CR, 33.3% PR).",Oral fludarabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14524733/),%,25.6,96300,DB01073,Fludarabine
,14524733,overall response rate,"Depending on the criteria used, the overall response rate was 46.2% (20.5% complete response [CR], 25.6% partial response [PR]) or 51.3% (17.9% CR, 33.3% PR).",Oral fludarabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14524733/),%,51.3,96301,DB01073,Fludarabine
,14524733,overall response rate,"Depending on the criteria used, the overall response rate was 46.2% (20.5% complete response [CR], 25.6% partial response [PR]) or 51.3% (17.9% CR, 33.3% PR).",Oral fludarabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14524733/),%,17.9,96302,DB01073,Fludarabine
,14524733,overall response rate,"Depending on the criteria used, the overall response rate was 46.2% (20.5% complete response [CR], 25.6% partial response [PR]) or 51.3% (17.9% CR, 33.3% PR).",Oral fludarabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14524733/),%,33.3,96303,DB01073,Fludarabine
,14524733,overall response,These results were similar to the 48% overall response rate reported in a similar historical control group treated with intravenous fludarabine.,Oral fludarabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14524733/),%,48,96304,DB01073,Fludarabine
,27991894,"SE, AUC","To test this hypothesis, we treated 218 patients (median age 50.7 years, male/female 50/50%) with fludarabine 40 mg/m2 once daily x4, each dose followed by IV Bu, randomized to 130 mg/m2 (N=107) or PK-guided to average daily SE, AUC of 6000 μM min (N=111), stratified for remission status and allo-grafting from HLA-matched donors.",Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27991894/),min·μM,6000,100001,DB01073,Fludarabine
,24463402,flow rate,"Analytes were recovered by liquid-liquid extraction and separated on a reverse phase C18 column (150mm×4.6mm i.d., 5μm) using methanol:0.1% formic acid buffer (70:30) as mobile phase at a flow rate of 1mL/min in isocratic mode.","Simultaneous quantification of idelalisib, fludarabine and lenalidomide in rat plasma by using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24463402/),[ml] / [min],1,103646,DB01073,Fludarabine
,34075614,area under the concentration-time curve (AUC),"Patients received standard full-dose melphalan in 17 transplants, with median area under the concentration-time curve (AUC) of 5.5 mg*h/L (range, 3.0-9.5 mg*h/L).",Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34075614/),[h·mg] / [l],5.5,105196,DB01073,Fludarabine
,34075614,AUC,Patients received test-dose melphalan in 23 transplants with a test-dose PK predicted full-dose AUC range of 2.9-16.8 mg*h/L.,Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34075614/),[h·mg] / [l],2.9-16.8,105197,DB01073,Fludarabine
,34075614,AUC,"In seven transplants where patients had baseline organ impairment, test-dose PK predicted higher exposure for standard full-dose (median AUC 13.8 mg*h/L).",Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34075614/),[h·mg] / [l],13.8,105198,DB01073,Fludarabine
,34075614,AUC,"Melphalan full-dose was adjusted in these patients, with achievement of desired target AUC (3.6-5.4 mg*h/L) and no excess toxicity.",Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34075614/),[h·mg] / [l],3.6-5.4,105199,DB01073,Fludarabine
,19862681,elimination half-life,"Mean (+/-SD) elimination half-life did not differ significantly between IV and oral dosage groups (11.3+/-4.0 vs 9.7+/-2.0 h, p=0.053).","Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19862681/),h,11.3,105315,DB01073,Fludarabine
,19862681,elimination half-life,"Mean (+/-SD) elimination half-life did not differ significantly between IV and oral dosage groups (11.3+/-4.0 vs 9.7+/-2.0 h, p=0.053).","Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19862681/),h,9.7,105316,DB01073,Fludarabine
,19862681,oral bioavailability,Estimated mean oral bioavailability of 2F-ara-A was 58%.,"Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19862681/),%,58,105317,DB01073,Fludarabine
<,20925957,AUC,We retrospectively compared outcomes of a consecutive series of 51 AML patients treated with oral busulfan (1 mg/kg every 6 hours for 4 days) and cyclophosphamide (60 mg/kg IV × 2 days) - (Bu/Cy) with 100 consecutive AML patients treated with pharmacokinetic targeted IV busulfan (AUC < 6000 μM/L*min per day × 4 days) and fludarabine (40 mg/m2 × 4 days) - (t-IV Bu/Flu).,Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20925957/),[μM] / [d·l·min],6000,109003,DB01073,Fludarabine
,26242764,time to neutrophil engraftment,"Median (range) time to neutrophil engraftment (>500 cells/µL) and platelet engraftment (>20,000/mm(3) ) were 15 (12-28) and 25 (17-30) days, respectively.",Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242764/),d,15,111482,DB01073,Fludarabine
,26242764,time to neutrophil engraftment,"Median (range) time to neutrophil engraftment (>500 cells/µL) and platelet engraftment (>20,000/mm(3) ) were 15 (12-28) and 25 (17-30) days, respectively.",Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242764/),d,25,111483,DB01073,Fludarabine
,26025482,area under the curve (AUC),"Bu regimen doses, adjusted to target an area under the curve (AUC) of 4000 μMol*minute per day in a first cohort (n = 12) and 5000 μMol*minute in a second cohort (n = 21).",Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26025482/),[min·μMol] / [d],4000,116023,DB01073,Fludarabine
,26025482,area under the curve (AUC),"Bu regimen doses, adjusted to target an area under the curve (AUC) of 4000 μMol*minute per day in a first cohort (n = 12) and 5000 μMol*minute in a second cohort (n = 21).",Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26025482/),min·μMol,5000,116024,DB01073,Fludarabine
,26025482,clearance,"The mean Bu clearance in our infant patients was found to be 3.67 ± 1.03 mL/minute/kg, and the test dose clearance was highly predictive of the regimen dose clearance.",Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26025482/),[ml] / [kg·min],3.67,116025,DB01073,Fludarabine
,26025482,AUC,The mean AUC achieved after the first single daily regimen dose was 3951 ± 1239 in the AUC 4000 cohort and 4884 ± 766 for the AUC 5000 cohort.,Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26025482/),,3951,116026,DB01073,Fludarabine
,26025482,AUC,The mean AUC achieved after the first single daily regimen dose was 3951 ± 1239 in the AUC 4000 cohort and 4884 ± 766 for the AUC 5000 cohort.,Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26025482/),,4884,116027,DB01073,Fludarabine
,26025482,Overall survival,"Overall survival of patients at 6 years after transplantation was 59.5% for the AUC 4000 cohort and 85.4% for the AUC 5000 cohort, with primary graft failure in the first cohort being a major contributor to morbidity.",Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26025482/),%,59,116028,DB01073,Fludarabine
,26025482,Overall survival,"Overall survival of patients at 6 years after transplantation was 59.5% for the AUC 4000 cohort and 85.4% for the AUC 5000 cohort, with primary graft failure in the first cohort being a major contributor to morbidity.",Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26025482/),%,85,116029,DB01073,Fludarabine
,26025482,AUC,The difference in clinical outcomes between the 2 cohorts supports the conclusion that targeting a higher Bu AUC of 5000 μMol*minute per day for 2 days improves donor engraftment in infants with nonmalignant conditions undergoing RIC HPCT without increasing toxicity.,Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26025482/),[min·μMol] / [d],5000,116030,DB01073,Fludarabine
≥,34044184,trough levels,"We observed lower day +100 NRM in those with both high F-ara-ADay-4 trough levels (≥40 ng/mL; >25th percentile) and low PM AUC0-8 hr (<34,235 hr ng/mL; <75th percentile), compared with high exposures to both agents (hazard ratio, 0.06; 95% CI, 0.01 to 0.48).",Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Adult Hematologic Malignancy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34044184/),[ng] / [ml],40,121238,DB01073,Fludarabine
<,34044184,AUC0-8 hr,"We observed lower day +100 NRM in those with both high F-ara-ADay-4 trough levels (≥40 ng/mL; >25th percentile) and low PM AUC0-8 hr (<34,235 hr ng/mL; <75th percentile), compared with high exposures to both agents (hazard ratio, 0.06; 95% CI, 0.01 to 0.48).",Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Adult Hematologic Malignancy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34044184/),[h·ng] / [ml],"34,235",121239,DB01073,Fludarabine
,30532055,area under the concentration-vs-time curve (AUC),"The RIC and MAC regimens were dosed at the average daily area under the concentration-vs-time curve (AUC) of 4000 µMol min and 5000-6000 µMol min, or total course AUC of 16,000 µMol min and 20,000-24,000 µMol min, respectively; PK-guided dosing removes overlap in systemic Bu exposure.",Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30532055/),min·µMol,4000,123452,DB01073,Fludarabine
,30532055,area under the concentration-vs-time curve (AUC),"The RIC and MAC regimens were dosed at the average daily area under the concentration-vs-time curve (AUC) of 4000 µMol min and 5000-6000 µMol min, or total course AUC of 16,000 µMol min and 20,000-24,000 µMol min, respectively; PK-guided dosing removes overlap in systemic Bu exposure.",Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30532055/),min·µMol,5000-6000,123453,DB01073,Fludarabine
,30532055,total course AUC,"The RIC and MAC regimens were dosed at the average daily area under the concentration-vs-time curve (AUC) of 4000 µMol min and 5000-6000 µMol min, or total course AUC of 16,000 µMol min and 20,000-24,000 µMol min, respectively; PK-guided dosing removes overlap in systemic Bu exposure.",Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30532055/),min·µMol,"16,000",123454,DB01073,Fludarabine
,30532055,total course AUC,"The RIC and MAC regimens were dosed at the average daily area under the concentration-vs-time curve (AUC) of 4000 µMol min and 5000-6000 µMol min, or total course AUC of 16,000 µMol min and 20,000-24,000 µMol min, respectively; PK-guided dosing removes overlap in systemic Bu exposure.",Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30532055/),min·µMol,"20,000-24,000",123455,DB01073,Fludarabine
greater,28684371,cumulative area under the curve (cAUC),"In the setting of malignancy, disease-free survival was highest at 1 year after HCT in subjects achieving a systemic f-ara-a cumulative area under the curve (cAUC) greater than 15 mg*hour/L compared to patients with a cAUC less than 15 mg*hour/L (82.6% versus 52.8% P = .04).",Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28684371/),[h·mg] / [l],15,124645,DB01073,Fludarabine
less,28684371,cAUC,"In the setting of malignancy, disease-free survival was highest at 1 year after HCT in subjects achieving a systemic f-ara-a cumulative area under the curve (cAUC) greater than 15 mg*hour/L compared to patients with a cAUC less than 15 mg*hour/L (82.6% versus 52.8% P = .04).",Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28684371/),[h·mg] / [l],15,124646,DB01073,Fludarabine
,29915216,area under the concentration-time curve (AUC) from dosing to infinity,"After the first dose of fludarabine at 40 mg/m2, the median (min-max) values for the area under the concentration-time curve (AUC) from dosing to infinity and the elimination half-life were 4696 (3056-10,477) ng·h/mL and 7.95 (4.78-10.88) h, respectively.",Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29915216/),[h·ng] / [ml],4696,125041,DB01073,Fludarabine
,29915216,elimination half-life,"After the first dose of fludarabine at 40 mg/m2, the median (min-max) values for the area under the concentration-time curve (AUC) from dosing to infinity and the elimination half-life were 4696 (3056-10,477) ng·h/mL and 7.95 (4.78-10.88) h, respectively.",Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29915216/),h,7.95,125042,DB01073,Fludarabine
,11304766,peak intracellular concentrations,"The median peak intracellular concentrations of ara-GTP were significantly different (P =.001) in responders (890 micromol/L, n = 6) and nonresponders (30 micromol/L, n = 6).","Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304766/),[μM] / [l],890,131689,DB01073,Fludarabine
,11304766,peak intracellular concentrations,"The median peak intracellular concentrations of ara-GTP were significantly different (P =.001) in responders (890 micromol/L, n = 6) and nonresponders (30 micromol/L, n = 6).","Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304766/),[μM] / [l],30,131690,DB01073,Fludarabine
,11304766,cellular elimination,"The cellular elimination of ara-GTP was slow (median, 35 hours; range, 18 to > 48 hours).","Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304766/),h,35,131691,DB01073,Fludarabine
,16545731,area under the concentration-time curve (AUC),"A test dose of IV Bu (0.8 mg/kg), anticipated to target an area under the concentration-time curve (AUC) of 800 to 1200 micromol.",Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16545731/),μM,800 to 1200,135851,DB01073,Fludarabine
,16545731,AUC,"min, was followed later by 2 daily doses adjusted according to the pharmacokinetics (PK) to target an AUC of 3200 to 4800 micromol.min.",Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16545731/),min·μM,3200 to 4800,135852,DB01073,Fludarabine
,16545731,AUC,"The median test dose AUC was 953 micromol.min (range, 439-1315 micromol.min).",Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16545731/),min·μM,953,135853,DB01073,Fludarabine
,16545731,AUC,"The median AUC of single daily doses was 3798 micromol.min (range, 1511-7254 micromol.min).",Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16545731/),min·μM,3798,135854,DB01073,Fludarabine
>,15501959,time to blood neutrophils,"Prolonged myelosuppression was observed with median time to blood neutrophils >/=200/microl of 28 (0 to 43) days and time to platelets >/=20,000/microl (untransfused) of 40 (24 to 120) days.","A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501959/),,200,139631,DB01073,Fludarabine
,15501959,time to blood neutrophils,"Prolonged myelosuppression was observed with median time to blood neutrophils >/=200/microl of 28 (0 to 43) days and time to platelets >/=20,000/microl (untransfused) of 40 (24 to 120) days.","A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501959/),d,28,139632,DB01073,Fludarabine
>,15501959,time to platelets,"Prolonged myelosuppression was observed with median time to blood neutrophils >/=200/microl of 28 (0 to 43) days and time to platelets >/=20,000/microl (untransfused) of 40 (24 to 120) days.","A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501959/),,"20,000",139633,DB01073,Fludarabine
,15501959,time to platelets,"Prolonged myelosuppression was observed with median time to blood neutrophils >/=200/microl of 28 (0 to 43) days and time to platelets >/=20,000/microl (untransfused) of 40 (24 to 120) days.","A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501959/),d,40,139634,DB01073,Fludarabine
,18981292,PFS,"Six responders received repeat therapy at relapse, and 5 responded again with a second median PFS of 10 months.",Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18981292/),month,10,142297,DB01073,Fludarabine
,18981292,CL,"Two-compartment population parameter estimates were 31.4 L/h, 65.8 L, 8.49 L/h, and 157 L for CL, V1, Q, and V2, respectively.",Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18981292/),[l] / [h],31.4,142298,DB01073,Fludarabine
,18981292,CL,"Two-compartment population parameter estimates were 31.4 L/h, 65.8 L, 8.49 L/h, and 157 L for CL, V1, Q, and V2, respectively.",Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18981292/),l,65.8,142299,DB01073,Fludarabine
,18981292,CL,"Two-compartment population parameter estimates were 31.4 L/h, 65.8 L, 8.49 L/h, and 157 L for CL, V1, Q, and V2, respectively.",Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18981292/),[l] / [h],8.49,142300,DB01073,Fludarabine
,18981292,V1,"Two-compartment population parameter estimates were 31.4 L/h, 65.8 L, 8.49 L/h, and 157 L for CL, V1, Q, and V2, respectively.",Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18981292/),[l] / [h],8.49,142301,DB01073,Fludarabine
,18981292,V1,"Two-compartment population parameter estimates were 31.4 L/h, 65.8 L, 8.49 L/h, and 157 L for CL, V1, Q, and V2, respectively.",Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18981292/),l,157,142302,DB01073,Fludarabine
,18981292,Q,"Two-compartment population parameter estimates were 31.4 L/h, 65.8 L, 8.49 L/h, and 157 L for CL, V1, Q, and V2, respectively.",Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18981292/),l,157,142303,DB01073,Fludarabine
,18981292,V2,"Two-compartment population parameter estimates were 31.4 L/h, 65.8 L, 8.49 L/h, and 157 L for CL, V1, Q, and V2, respectively.",Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18981292/),l,157,142304,DB01073,Fludarabine
,30327943,area under the curve,Variability was extensive where area under the curve ranged from 10 to 66 mg h/L.,Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327943/),[h·mg] / [l],10 to 66,149371,DB01073,Fludarabine
,30327943,volumes of distribution,"The typical volumes of distribution of the central (V1), peripheral (V2), and second peripheral (V3) compartments were 39 ± 8%, 20 ± 11%, and 50 ± 9% L/70 kg respectively.",Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327943/),%,39,149372,DB01073,Fludarabine
,30327943,V2,"The typical volumes of distribution of the central (V1), peripheral (V2), and second peripheral (V3) compartments were 39 ± 8%, 20 ± 11%, and 50 ± 9% L/70 kg respectively.",Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327943/),%,39,149373,DB01073,Fludarabine
,30327943,V2,"The typical volumes of distribution of the central (V1), peripheral (V2), and second peripheral (V3) compartments were 39 ± 8%, 20 ± 11%, and 50 ± 9% L/70 kg respectively.",Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327943/),%,20,149374,DB01073,Fludarabine
,30327943,V3,"The typical volumes of distribution of the central (V1), peripheral (V2), and second peripheral (V3) compartments were 39 ± 8%, 20 ± 11%, and 50 ± 9% L/70 kg respectively.",Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327943/),[%·l] / [70·kg],50,149375,DB01073,Fludarabine
,30327943,Intercompartmental clearances,"Intercompartmental clearances between V1 and V2, and V1 and V3, were 8.6 ± 8% and 3.8 ± 13% L/h/70 kg, respectively.",Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327943/),%,8.6,149376,DB01073,Fludarabine
,30327943,Intercompartmental clearances,"Intercompartmental clearances between V1 and V2, and V1 and V3, were 8.6 ± 8% and 3.8 ± 13% L/h/70 kg, respectively.",Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327943/),[%·l] / [70·h·kg],3.8,149377,DB01073,Fludarabine
,30327943,V1,"Intercompartmental clearances between V1 and V2, and V1 and V3, were 8.6 ± 8% and 3.8 ± 13% L/h/70 kg, respectively.",Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327943/),%,8.6,149378,DB01073,Fludarabine
,30327943,V1,"Intercompartmental clearances between V1 and V2, and V1 and V3, were 8.6 ± 8% and 3.8 ± 13% L/h/70 kg, respectively.",Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327943/),[%·l] / [70·h·kg],3.8,149379,DB01073,Fludarabine
,22888522,AUC(0-4),"The Ara-C dose for Group A was 3g/m2 x 2, and the AUC(0-4) was 5.131 +/- 0.936.",Sequential arabinosylcytosin with or without fludarabine in paracmastic patients with acute myeloid leukemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22888522/),,5.131,157904,DB01073,Fludarabine
,22888522,AUC(0-4),"The Ara-C dose for Group B was 2g/m2 x 2, and the AUC(0-4) was 12.245 +/- 3.863.",Sequential arabinosylcytosin with or without fludarabine in paracmastic patients with acute myeloid leukemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22888522/),,12.245,157905,DB01073,Fludarabine
,26433392,flow rate,"The analysis was carried out using a reversed phase C18 column with a mobile phase consisting of methanol-water (65:35, v/v) at a flow rate of 1 mL/min.",Development and Validation of a High Pressure Liquid Chromatography-UV Method for the Determination of Treosulfan and Its Epoxy Metabolites in Human Plasma and Its Application in Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26433392/),[ml] / [min],1,158208,DB01073,Fludarabine
,16618945,complete response rate,"The complete response rate improved from 35% after fludarabine induction to 79.4% after alemtuzumab consolidation, including 19 patients (56%) who achieved MRD negativity.",Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16618945/),%,35,163691,DB01073,Fludarabine
,16618945,complete response rate,"The complete response rate improved from 35% after fludarabine induction to 79.4% after alemtuzumab consolidation, including 19 patients (56%) who achieved MRD negativity.",Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16618945/),%,79.4,163692,DB01073,Fludarabine
,16275653,overall response rate,The overall response rate was 67%.,Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16275653/),%,67,166536,DB01073,Fludarabine
,1737352,t1/2,"The median rate of ara-CTP elimination was slightly faster after fludarabine treatment (t1/2, 6.7 versus 5.8 h), suggesting that catabolism of ara-CTP was not responsible for the increased ara-CTP area under the curve.",Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1737352/),h,6.7,170083,DB01073,Fludarabine
,1737352,t1/2,"The median rate of ara-CTP elimination was slightly faster after fludarabine treatment (t1/2, 6.7 versus 5.8 h), suggesting that catabolism of ara-CTP was not responsible for the increased ara-CTP area under the curve.",Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1737352/),h,5.8,170084,DB01073,Fludarabine
,26947201,trough serum concentration,"At cycle five, the geometric mean trough serum concentration in patients given subcutaneous rituximab was non-inferior to that in patients given intravenous rituximab (97·5 μg/mL vs 61·5 μg/mL), with an adjusted geometric mean ratio of 1·53 (90% CI 1·27-1·85).","Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26947201/),[μg] / [ml],97·5,171354,DB01073,Fludarabine
,26947201,trough serum concentration,"At cycle five, the geometric mean trough serum concentration in patients given subcutaneous rituximab was non-inferior to that in patients given intravenous rituximab (97·5 μg/mL vs 61·5 μg/mL), with an adjusted geometric mean ratio of 1·53 (90% CI 1·27-1·85).","Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26947201/),[μg] / [ml],61·5,171355,DB01073,Fludarabine
,34022093,Overall survival,"Busulfan pharmacokinetics were measured to target 4000 μmol*min/day in the first 30 patients; this was increased to 5000 μmol*min/day in the subsequent 10 in efforts to further decrease relapse risk RESULTS: Overall survival at two- and five-years post-HCT was 67% and 51%, respectively.","Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34022093/),%,67,172014,DB01073,Fludarabine
,34022093,Overall survival,"Busulfan pharmacokinetics were measured to target 4000 μmol*min/day in the first 30 patients; this was increased to 5000 μmol*min/day in the subsequent 10 in efforts to further decrease relapse risk RESULTS: Overall survival at two- and five-years post-HCT was 67% and 51%, respectively.","Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34022093/),%,51,172015,DB01073,Fludarabine
>,34022093,AUC,Trends toward improved survival were seen in patients transplanted for myeloid disease using bone marrow as stem cell source who achieved a busulfan AUC > 4000 μmol*min/day with two-year relapse-free survival approaching 80% CONCLUSIONS:,"Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34022093/),[min·μM] / [d],4000,172016,DB01073,Fludarabine
,11920267,AUC((0-24 h)),There was a marginal increase in total systemic availability of fludarabine phosphate when administered orally on a fed stomach (2-F-ara-A AUC((0-24 h)) = 3.28 +/- 1.48 microg.h/ml) compared to a fasted stomach (2-F-ara-A AUC((0-24 h)) = 3.05 +/- 1.56 microg.h/ml).,The bioavailability of oral fludarabine phosphate is unaffected by food. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920267/),[h·μg] / [ml],3.28,175588,DB01073,Fludarabine
,11920267,AUC((0-24 h)),There was a marginal increase in total systemic availability of fludarabine phosphate when administered orally on a fed stomach (2-F-ara-A AUC((0-24 h)) = 3.28 +/- 1.48 microg.h/ml) compared to a fasted stomach (2-F-ara-A AUC((0-24 h)) = 3.05 +/- 1.56 microg.h/ml).,The bioavailability of oral fludarabine phosphate is unaffected by food. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920267/),[h·μg] / [ml],3.05,175589,DB01073,Fludarabine
,11920267,Time to peak plasma concentration,Time to peak plasma concentration was slightly extended by the presence of food (2.2 +/- 1.0 versus 1.3 +/- 0.74 h) but the terminal half-life was unaffected.,The bioavailability of oral fludarabine phosphate is unaffected by food. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920267/),h,2.2,175590,DB01073,Fludarabine
,11920267,Time to peak plasma concentration,Time to peak plasma concentration was slightly extended by the presence of food (2.2 +/- 1.0 versus 1.3 +/- 0.74 h) but the terminal half-life was unaffected.,The bioavailability of oral fludarabine phosphate is unaffected by food. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920267/),h,1.3,175591,DB01073,Fludarabine
,20601034,clearance,"Dose- and weight-corrected Bu PK parameters (clearance, 0.173 ± 0.051 L/hour · kg; volume of distribution, 0.71 ± 0.17 L/kg; half-life time, 3.0 ± 0.7 hours) did not differ among treatment protocols (all P >.14) and remained stable between the first and mid-cycle doses.",Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20601034/),[l] / [h·kg],0.173,177221,DB01073,Fludarabine
,20601034,volume of distribution,"Dose- and weight-corrected Bu PK parameters (clearance, 0.173 ± 0.051 L/hour · kg; volume of distribution, 0.71 ± 0.17 L/kg; half-life time, 3.0 ± 0.7 hours) did not differ among treatment protocols (all P >.14) and remained stable between the first and mid-cycle doses.",Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20601034/),[l] / [kg],0.71,177222,DB01073,Fludarabine
,20601034,half-life time,"Dose- and weight-corrected Bu PK parameters (clearance, 0.173 ± 0.051 L/hour · kg; volume of distribution, 0.71 ± 0.17 L/kg; half-life time, 3.0 ± 0.7 hours) did not differ among treatment protocols (all P >.14) and remained stable between the first and mid-cycle doses.",Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20601034/),h,3.0,177223,DB01073,Fludarabine
,15876260,clearance,The average dialysis clearance was 33.85 ml/min which is about 25% of the clearance in patients without renal failure.,Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15876260/),[ml] / [min],33.85,178607,DB01073,Fludarabine
,18766965,MTD,The duration of MTD for gemcitabine was 12 h.,"Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18766965/),h,12,195846,DB01073,Fludarabine
,22184378,progression-free survival,Median progression-free survival was 25 months.,Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22184378/),month,25,197097,DB01073,Fludarabine
,20555126,Trough levels,"Trough levels of 4 patients on three-monthly schedule maintenance therapy remained constant, with a median concentration of 6 mu g/mL (range 0.5-11.7 microg/mL).",Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20555126/),[g·mu] / [ml],6,204913,DB01073,Fludarabine
,20555126,elimination half-life at steady state,"The elimination half-life at steady state of rituximab in all patients was estimated to be 19.2 (+/- 15.2%) days with a between-subject variability of 54%, indicating wide variability.",Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20555126/),d,19.2,204914,DB01073,Fludarabine
,20383215,area-under-the-curve (AUC((0-∞))),"Median (range) F-ara-A area-under-the-curve (AUC((0-∞))) was 5.0 μg h/mL (2.0-11.0), clearance 15.3 L/h (6.2-36.6), C(min) 55 ng/mL (17-166) and concentration on day(zero) 16.0 ng/mL (0.1-144.1).",High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20383215/),[h·μg] / [ml],5.0,207060,DB01073,Fludarabine
,20383215,clearance,"Median (range) F-ara-A area-under-the-curve (AUC((0-∞))) was 5.0 μg h/mL (2.0-11.0), clearance 15.3 L/h (6.2-36.6), C(min) 55 ng/mL (17-166) and concentration on day(zero) 16.0 ng/mL (0.1-144.1).",High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20383215/),[l] / [h],15.3,207061,DB01073,Fludarabine
,20383215,C(min),"Median (range) F-ara-A area-under-the-curve (AUC((0-∞))) was 5.0 μg h/mL (2.0-11.0), clearance 15.3 L/h (6.2-36.6), C(min) 55 ng/mL (17-166) and concentration on day(zero) 16.0 ng/mL (0.1-144.1).",High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20383215/),[ng] / [ml],55,207062,DB01073,Fludarabine
,20383215,concentration,"Median (range) F-ara-A area-under-the-curve (AUC((0-∞))) was 5.0 μg h/mL (2.0-11.0), clearance 15.3 L/h (6.2-36.6), C(min) 55 ng/mL (17-166) and concentration on day(zero) 16.0 ng/mL (0.1-144.1).",High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20383215/),[ng] / [ml],16.0,207063,DB01073,Fludarabine
greater,20383215,AUC((0-∞)),Patients with an AUC((0-∞)) greater than 6.5 μg h/mL had 4.56 greater risk of TRM and significantly lower OS.,High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20383215/),[h·μg] / [ml],6.5,207064,DB01073,Fludarabine
,9855320,total clearance,"The mean+/-SD total clearance, volume of distribution at steady state, and beta-half-life were 13.68+/-5.1 L/hour, 170.08+/-86.5 L, and 10.9+/-3.1 hours, respectively.",The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855320/),[l] / [h],13.68,207466,DB01073,Fludarabine
,9855320,volume of distribution at steady state,"The mean+/-SD total clearance, volume of distribution at steady state, and beta-half-life were 13.68+/-5.1 L/hour, 170.08+/-86.5 L, and 10.9+/-3.1 hours, respectively.",The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855320/),l,170.08,207467,DB01073,Fludarabine
,9855320,beta-half-life,"The mean+/-SD total clearance, volume of distribution at steady state, and beta-half-life were 13.68+/-5.1 L/hour, 170.08+/-86.5 L, and 10.9+/-3.1 hours, respectively.",The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855320/),h,10.9,207468,DB01073,Fludarabine
,9855320,terminal half-life,"Fludarabine pharmacokinetics in patients with RA are characterized by an intermediate-length distribution phase (approximately 40 min), terminal half-life of 10.9 hours, and significant amount of tissue distribution.",The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855320/),h,10.9,207469,DB01073,Fludarabine
,10334546,Bioavailability,"Bioavailability (approximately 55%, with low intraindividual variation) and time to Cmax were dose independent.","Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with ""low-grade"" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10334546/),%,55,213267,DB01073,Fludarabine
,15073038,CR rate,The CR rate for 54 patients with active disease was 85%.,"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073038/),%,85,213392,DB01073,Fludarabine
,15073038,clearance,"Median busulfan clearance was 109 mL/min/m2 and median daily area-under-the-plasma-concentration-versus-time-curve was 4871 micromol-min, with negligible interdose variability in pharmacokinetic parameters.","Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073038/),[ml] / [m2·min],109,213393,DB01073,Fludarabine
,15073038,area-under-the-plasma-concentration-versus-time-curve,"Median busulfan clearance was 109 mL/min/m2 and median daily area-under-the-plasma-concentration-versus-time-curve was 4871 micromol-min, with negligible interdose variability in pharmacokinetic parameters.","Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073038/),μmol-min,4871,213394,DB01073,Fludarabine
,31212080,area under the curve (AUC),"On this phase II multicenter study, 63 patients (40 unrelated donors and 23 matched related donors) received a uniform conditioning regimen consisting of fludarabine i.v. (days -7 to -3), BU targeted to a daily area under the curve (AUC) of 4000 μM/min (days -6 to -3) after the administration of a 25-mg/m2 i.v. test dose on 1 day between days -14 to -9, and antithymocyte globulin (days -6, -5, and -4 (2 doses for matched related donors and 3 for matched unrelated donors only).",A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31212080/),[μM] / [min],4000,218958,DB01073,Fludarabine
,31212080,overall survival,"The probability of overall survival at 2 and 5 years was 45.7% (95% CI, 34.9%-59.9%) and 31.2% (95% CI, 21.3% to 45.8%), respectively, for the entire group with a median overall survival of 19.2 months (95% CI, 8.7 to 37.5).",A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31212080/),month,19.2,218959,DB01073,Fludarabine
,31212080,AUC,"In summary, we demonstrated the feasibility of a novel reduced-intensity conditioning regimen with test dose BU targeted to an AUC of 4000 μM/min.",A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31212080/),[μM] / [min],4000,218960,DB01073,Fludarabine
,29753157,relapse,One-year relapse was 38% for AML and 13% for MDS.,"Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29753157/),%,38,219180,DB01073,Fludarabine
,29753157,relapse,One-year relapse was 38% for AML and 13% for MDS.,"Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29753157/),,13,219181,DB01073,Fludarabine
exceed,23716541,trough level,"Although rituximab trough levels increased progressively with each cycle, only by cycle 4 did the median trough level exceed 10 ug/mL.",Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23716541/),[ug] / [ml],10,220088,DB01073,Fludarabine
,23716541,half-life,"The median half-life of rituximab during cycle 1 was 27 hours, compared to 199 hours during cycle 4 (P<0.0001).",Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23716541/),h,27,220089,DB01073,Fludarabine
,23716541,half-life,"The median half-life of rituximab during cycle 1 was 27 hours, compared to 199 hours during cycle 4 (P<0.0001).",Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23716541/),h,199,220090,DB01073,Fludarabine
,18309944,peak intracellular concentrations,"The median peak intracellular concentrations of ara-GTP were significantly different (P = .0003) between responders (440 micromol/L; range, 35 to 1,438 micromol/L; n = 10) and nonresponders (50 micromol/L; range, 22 to 178 micromol/L; n = 15).",Phase I trial of nelarabine in indolent leukemias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18309944/),[μM] / [l],440,224357,DB01073,Fludarabine
,18309944,peak intracellular concentrations,"The median peak intracellular concentrations of ara-GTP were significantly different (P = .0003) between responders (440 micromol/L; range, 35 to 1,438 micromol/L; n = 10) and nonresponders (50 micromol/L; range, 22 to 178 micromol/L; n = 15).",Phase I trial of nelarabine in indolent leukemias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18309944/),[μM] / [l],50,224358,DB01073,Fludarabine
,28481355,clearance,Patients carrying a 5'-UTR polymorphism in NT5E gene (rs2295890 G>C) exhibited significantly lower plasma F-araA clearance compared to those with wild-type genotype (7.12 vs 5.03 L/h/m2 (29%) P<0.05).,Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28481355/),[l] / [h·m2],7.12,225399,DB01073,Fludarabine
,28481355,clearance,Patients carrying a 5'-UTR polymorphism in NT5E gene (rs2295890 G>C) exhibited significantly lower plasma F-araA clearance compared to those with wild-type genotype (7.12 vs 5.03 L/h/m2 (29%) P<0.05).,Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28481355/),[l] / [h·m2],5.03,225400,DB01073,Fludarabine
>,28481355,AUC,"Of all the outcome parameters evaluated (engraftment, rejection/graft failure, GvHD, TRM, OS), high F-araA AUC (>29.4 μm*h) was the only significant factor associated with the development of aGvHD by both univariate and multivariate analysis (P=0.02).",Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28481355/),h·μm,29.4,225401,DB01073,Fludarabine
,3478543,terminal rate of elimination (t1/2),The median terminal rate of elimination (t1/2) of F-ara-A was 8.4 hr compared to 2.2 hr for ara-C.,Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3478543/),h,8.4,226337,DB01073,Fludarabine
,3478543,terminal rate of elimination (t1/2),The median terminal rate of elimination (t1/2) of F-ara-A was 8.4 hr compared to 2.2 hr for ara-C.,Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3478543/),h,2.2,226338,DB01073,Fludarabine
,3478543,t1/2,The median t1/2 for F-ara-ATP in CLB was 12.2 hr relative to 1.9 hr for ara-CTP.,Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3478543/),h,12.2,226339,DB01073,Fludarabine
,3478543,t1/2,The median t1/2 for F-ara-ATP in CLB was 12.2 hr relative to 1.9 hr for ara-CTP.,Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3478543/),h,1.9,226340,DB01073,Fludarabine
,17192496,area under the curve (AUC),"Intravenous dosing resulted in a median area under the curve (AUC) of 28.3 microg x h/mL (range, 9.96-70.4) and an oral AUC of 16.7 microg x h/mL (range, 9.38-35.3).",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[h·μg] / [ml],28.3,229900,DB01073,Fludarabine
,17192496,oral AUC,"Intravenous dosing resulted in a median area under the curve (AUC) of 28.3 microg x h/mL (range, 9.96-70.4) and an oral AUC of 16.7 microg x h/mL (range, 9.38-35.3).",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[h·μg] / [ml],16.7,229901,DB01073,Fludarabine
,17192496,Cmax,"Cmax after intravenous and oral dosing was 12.18 and 5.29 microg/mL, respectively.",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[μg] / [ml],12.18,229902,DB01073,Fludarabine
,17192496,Cmax,"Cmax after intravenous and oral dosing was 12.18 and 5.29 microg/mL, respectively.",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[μg] / [ml],5.29,229903,DB01073,Fludarabine
,17192496,oral bioavailability,"The median oral bioavailability was 72.3% (20.5%-172%), with 8-fold variability.",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),%,72.3,229904,DB01073,Fludarabine
< or =,17192496,oral bioavailability,Five patients (28%) had an oral bioavailability < or = 50%.,Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),%,50,229905,DB01073,Fludarabine
<,17192496,AUC(0-12),"At time of oral pharmacokinetics, 15 patients (83%) had an AUC(0-12) < 30 microg x h/mL.",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[h·μg] / [ml],30,229906,DB01073,Fludarabine
,34403790,AUC target,"After i.v. administration, an optimal Bu therapeutic window (AUC target of 16,000 to 24,000 μM·minute) has been identified.",Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34403790/),min·μM,"16,000 to 24,000",231294,DB01073,Fludarabine
,34403790,AUC,"Patients received a total Bu dose to achieve a target AUC of 16,000 μM·minute in combination with Flu and thiotepa.",Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34403790/),min·μM,"16,000",231295,DB01073,Fludarabine
,34403790,time to absolute neutrophil count recovery,"The median time to absolute neutrophil count recovery and transfusion-independent platelet count recovery was 23 days (range, 15 to 42 days) and 29 days (range, 14 to 97 days), respectively.",Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34403790/),d,23,231296,DB01073,Fludarabine
,34403790,transfusion-independent platelet count recovery,"The median time to absolute neutrophil count recovery and transfusion-independent platelet count recovery was 23 days (range, 15 to 42 days) and 29 days (range, 14 to 97 days), respectively.",Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34403790/),d,29,231297,DB01073,Fludarabine
,31701524,area under the curve from zero to infinity (AUC(0-∞) ),"For each increase in treosulfan area under the curve from zero to infinity (AUC(0-∞) ) of 1,000 mg hour/L the hazard ratio (95% confidence interval) for mortality increase was 1.46 (1.23-1.74), and the hazard ratio for low engraftment was 0.61 (0.36-1.04).",Proposed Therapeutic Range of Treosulfan in Reduced Toxicity Pediatric Allogeneic Hematopoietic Stem Cell Transplant Conditioning: Results From a Prospective Trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31701524/),[h·mg] / [l],"1,000",234028,DB01073,Fludarabine
,31701524,AUC(0-∞),"A cumulative AUC(0-∞) of 4,800 mg hour/L maximized the probability of success (> 20% engraftment and no mortality) at 82%.",Proposed Therapeutic Range of Treosulfan in Reduced Toxicity Pediatric Allogeneic Hematopoietic Stem Cell Transplant Conditioning: Results From a Prospective Trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31701524/),[h·mg] / [l],"4,800",234029,DB01073,Fludarabine
,8890711,half-life,"Recent pharmacokinetic studies have revealed a prolonged release of the cytotoxic agent cytosine arabinoside (araC) from hepatocytes into the systemic circulation, resulting in a half-life of approximately 24 h for araC.","Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8890711/),h,24,241594,DB01073,Fludarabine
,18215782,Plasma AUC,"Plasma AUC varied 3.6-fold (2184-7794 microM.min, median 4699 microM.min).",High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18215782/),min·μM,2184-7794,251757,DB01073,Fludarabine
,18215782,Plasma AUC,"Plasma AUC varied 3.6-fold (2184-7794 microM.min, median 4699 microM.min).",High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18215782/),min·μM,4699,251758,DB01073,Fludarabine
>,18215782,AUC,"Patients with an AUC >6000 microM.min had lower overall survival (OS) than those with AUC < or =6000 microM.min at 12 months (38% versus 74%) and 36 months (23% versus 68%, P < .001).",High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18215782/),min·μM,6000,251759,DB01073,Fludarabine
<,18215782,AUC,"Patients with an AUC >6000 microM.min had lower overall survival (OS) than those with AUC < or =6000 microM.min at 12 months (38% versus 74%) and 36 months (23% versus 68%, P < .001).",High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18215782/),min·μM,6000,251760,DB01073,Fludarabine
< or =,18215782,AUC,Nonrelapse mortality (NRM) at 100 days (6% versus 19%) and progression free survival (PFS; 58% versus 16%) at 3 years were better with AUC < or =6000 microM.min.,High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18215782/),min·μM,6000,251761,DB01073,Fludarabine
,15976066,concentrations at steady state (Css),The average plasma BU concentrations at steady state (Css) ranged from 745 to 2422 ng/ml.,An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15976066/),[ng] / [ml],745 to 2422,254351,DB01073,Fludarabine
>,15976066,Css,"Four of seven patients had BU Css >1000 ng/ml, the previously defined concentration associated with an increased risk of regimen-related toxicity (RRT).",An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15976066/),[ng] / [ml],1000,254352,DB01073,Fludarabine
<,15976066,Css,"On the other hand, no severe toxicity greater than grade II except stomatitis was observed in the remaining patients whose Css were <1000 ng/ml.",An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15976066/),[ng] / [ml],1000,254353,DB01073,Fludarabine
,19543331,area under the curve (AUC),Targeted BU area under the curve (AUC) range was 4800-5200 microM min.,Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19543331/),min·μM,4800-5200,255668,DB01073,Fludarabine
below,19543331,AUC,An AUC below the therapeutic value of 4000 microM min was observed in 23% of the patients receiving a wt-based dose and in 0% of patients whose dose was calculated on the basis of the test dose (P=0.03).,Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19543331/),min·μM,4000,255669,DB01073,Fludarabine
,19671874,LSS times,"The LSS times chosen were 0.583, 1.5, 6.5, and 24 hours after the start of the 30-minute fludarabine infusion.",A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19671874/),h,0.583,261767,DB01073,Fludarabine
,19671874,LSS times,"The LSS times chosen were 0.583, 1.5, 6.5, and 24 hours after the start of the 30-minute fludarabine infusion.",A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19671874/),h,1.5,261768,DB01073,Fludarabine
,19671874,LSS times,"The LSS times chosen were 0.583, 1.5, 6.5, and 24 hours after the start of the 30-minute fludarabine infusion.",A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19671874/),h,6.5,261769,DB01073,Fludarabine
,19671874,LSS times,"The LSS times chosen were 0.583, 1.5, 6.5, and 24 hours after the start of the 30-minute fludarabine infusion.",A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19671874/),h,24,261770,DB01073,Fludarabine
,11349741,maximum concentrations,"No significant differences were found between subcutaneous and intravenous administration in median (interquartile range) maximum concentrations of 0.51 (0.38-0.56) and 0.75 (0.52-0.91) mg/L, respectively, or in fitted area under the concentration-time curves from 0-24 hours of 4.65 (4.17-4.98) and 4.55 (3.5-4.94) mg x hour/L, respectively.",Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11349741/),[mg] / [l],0.51,265385,DB01073,Fludarabine
,11349741,maximum concentrations,"No significant differences were found between subcutaneous and intravenous administration in median (interquartile range) maximum concentrations of 0.51 (0.38-0.56) and 0.75 (0.52-0.91) mg/L, respectively, or in fitted area under the concentration-time curves from 0-24 hours of 4.65 (4.17-4.98) and 4.55 (3.5-4.94) mg x hour/L, respectively.",Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11349741/),[mg] / [l],0.75,265386,DB01073,Fludarabine
,11349741,area under the concentration-time curves from 0-24 hours,"No significant differences were found between subcutaneous and intravenous administration in median (interquartile range) maximum concentrations of 0.51 (0.38-0.56) and 0.75 (0.52-0.91) mg/L, respectively, or in fitted area under the concentration-time curves from 0-24 hours of 4.65 (4.17-4.98) and 4.55 (3.5-4.94) mg x hour/L, respectively.",Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11349741/),[h·mg] / [l],4.65,265387,DB01073,Fludarabine
,11349741,area under the concentration-time curves from 0-24 hours,"No significant differences were found between subcutaneous and intravenous administration in median (interquartile range) maximum concentrations of 0.51 (0.38-0.56) and 0.75 (0.52-0.91) mg/L, respectively, or in fitted area under the concentration-time curves from 0-24 hours of 4.65 (4.17-4.98) and 4.55 (3.5-4.94) mg x hour/L, respectively.",Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11349741/),[h·mg] / [l],4.55,265388,DB01073,Fludarabine
,11349741,Bioavailability,Bioavailability of F-ara-A after subcutaneous dosing was approximately 105% of the bioavailability after intravenous administration.,Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11349741/),%,105,265389,DB01073,Fludarabine
,22511498,complete remission,"Significantly higher complete remission rates were observed in female patients (86 vs. 47%; Odds Ratio 6.8, 95% CI: 1.12; 41.82; P=0.05).","Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511498/),,86,269684,DB01073,Fludarabine
,22511498,complete remission,"Significantly higher complete remission rates were observed in female patients (86 vs. 47%; Odds Ratio 6.8, 95% CI: 1.12; 41.82; P=0.05).","Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511498/),,47,269685,DB01073,Fludarabine
,22511498,area under the curve,"Rituximab pharmacokinetic analysis showed a high variability ranging over almost 1 order of magnitude at maintenance cycle 1 (area under the curve 1,540-12,025 g/L*days).","Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511498/),[g] / [d·l],"1,540-12,025",269686,DB01073,Fludarabine
below,22511498,C(trough),"A decline in rituximab C(trough) below 25,000 ng/mL was observed 9.5 to 62 months before clinical relapse (P=0.008).","Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22511498/),[ng] / [ml],"25,000",269687,DB01073,Fludarabine
